Peptimmune, Inc.
64 Sidney Street
Suite 380
Cambridge
Massachusetts
02139-4136
United States
Tel: 617-715-8000
Fax: 617-661-8855
Website: http://www.peptimmune.com/
Email: info@peptimmune.com
17 articles about Peptimmune, Inc.
-
Merck Serono Buys Potential Copaxone Competitor from Bankrupt Peptimmune, Inc.
9/19/2011
-
Peptimmune, Inc. Files Under Chapter 7
3/23/2011
-
Peptimmune, Inc. Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
10/4/2010
-
Peptimmune, Inc. Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
8/25/2009
-
Peptimmune, Inc. Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis; Payments Could Total More Than $500 Million
1/15/2009
-
'Unprecedented' Biotech Bankruptcies Erupt Amid Finance Crisis
11/21/2008
-
Peptimmune, Inc. Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
9/17/2008
-
Peptimmune, Inc. Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
7/31/2008
-
Peptimmune, Inc. Announces the Second Close of Series D Private Financing
7/16/2008
-
Peptimmune, Inc. Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients
6/17/2008
-
Peptimmune, Inc. Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
6/9/2008
-
Peptimmune, Inc. Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3/19/2008
-
Peptimmune, Inc. Announces First Close of Series D Private Financing
1/17/2008
-
Peptimmune, Inc. Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
10/3/2007
-
Peptimmune, Inc. Appoints Fredric Price as Chairman and Reorganizes its Board of Directors
9/18/2007
-
Peptimmune, Inc. To Provide A Progress Report On The Company's Clinical And Non-Clinical Programs
2/9/2007
-
Peptimmune, Inc. And Orphan Europe Partner To Develop Specific Immunotherapy For Life-Threatening Skin Disease
11/9/2006